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Abstract
Background: Macrophage migration inhibitory factor (MIF) has been proposed to play a detrimental role in stroke.
We recently showed that MIF promotes neuronal death and aggravates neurological deficits during the first week
after experimental stroke, in mice. Since MIF regulates tissue inflammation, we studied the putative role of MIF in
post-stroke inflammation.
Methods: We subjected C57BL/6 mice, Mif
-/- (MIF-KO) or Mif
+/+ (WT), to a transient occlusion of the right middle
cerebral artery (tMCAo) or sham-surgery. We studied MIF expression, GFAP expression and the number of CD74-
positive cells in the ischemic brain hemisphere 7 days after tMCAo using primarily immunohistochemistry. We
determined IFN-g, IL-2, IL-4, IL-5, IL-10, IL-12, KC/CXCL-1 and TNF-a protein levels in the brain (48 h after surgery)
and serum (48 h and 7 days after surgery) by a multiplex immunoassay.
Results: We observed that MIF accumulates in neurons and astrocytes of the peri-infarct region, as well as in
microglia/macrophages of the infarct core up to 7 days after stroke. Among the inflammatory mediators analyzed,
we found a significant increase in cerebral IL-12 and KC levels after tMCAo, in comparison to sham-surgery.
Importantly, the deletion of Mif did not significantly affect the levels of the cytokines evaluated, in the brain or
serum. Moreover, the spleen weight 48 h and 7 days subsequent to tMCAo was similar in WT and MIF-KO mice.
Finally, the extent of GFAP immunoreactivity and the number of MIF receptor (CD74)-positive cells within the
ischemic brain hemisphere did not differ significantly between WT and MIF-KO mice subjected to tMCAo.
Conclusions: We conclude that MIF does not affect major components of the inflammatory/immune response
during the first week after experimental stroke. Based on present and previous evidence, we propose that the
deleterious MIF-mediated effects in stroke depend primarily on an intraneuronal and/or interneuronal action.
Keywords: cluster of differentiation 74 (CD74), cytokines, glial fibrillary acidic protein (GFAP), galectin-3 (Gal-3)/Mac-
2, macrophage migration inhibitory factor (MIF), transient middle cerebral artery occlusion (tMCAo)
Background
Focal cerebral ischemia, experimentally induced in
rodents and in the clinical setting, causes an early and
sustained activation of inflammatory and immune cas-
cades, both locally in the brain and outside the brain
[1]. These cascades affect cerebral cell death and also
are believed to integrate mechanisms of later functional
recovery [2]. Dynamic alterations in the production/
release of several pro and anti-inflammatory cytokines,
including chemokines, in the brain and periphery are
part of the inflammatory/immune response following
stroke [3]. Interleukin (IL)1-b expression increases in
the rodent brain subsequent to middle cerebral artery
occlusion (MCAo), [4], both promoting cell death [5,6]
and repressing recovery of neurological function [7].
Tumor necrosis factor (TNF)-a may exert both
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exact spatial-temporal expression profile [8]. In stroke
patients, increased cerebrospinal fluid and/or circulating
IL-1b, IL-6, IL-10, and CXCL-1 (CINC-1/IL-8), mono-
cyte chemoattractant protein-1, and TNF-a concentra-
tions have been reported [3], and IL-6 in particular
identified as a predictor of stroke outcome [9]. Regula-
tory cytokine pathways and signaling may mediate or
co-exist with glial activation/gliosis and the recruitment
of peripheral immune cells to the locus of injury. The
formation of an astroglial scar, typically during the first
week after stroke, is generally believed to beneficially
constrain damage expansion. Moreover, it may be neces-
sary for or repress neuroregeneration and repair [10,11].
Similarly, detrimental and beneficial actions of activated
microglia/invading macrophages [12-14] and other
immune cells have been reported [15]. The inflamma-
tory/immune response following stroke also is thought
to comprise an induced peripheral immunodepression
[16], given for instance by a shift from T helper cell
(Th)1 to Th2 cytokine production [17] and splenic atro-
phy [18].
Macrophage Migration Inhibitory Factor (MIF) is a
multifunctional, ubiquitous protein. Among its many
identified modes of action, MIF is an upstream regulator
of inflammatory-immune processes [19]. In particular,
MIF has a pro-inflammatory action in local and systemic
inflammatory and immune responses outside the brain,
which can be highly detrimental, for example, in athero-
sclerosis, rheumatoid arthritis [20,21] and sepsis [22].
Here, multiple mechanisms are involved, among which
MIF promotes the expression of pro-inflammatory cyto-
kines [19], leukocyte adhesion and infiltration [21] and
immune cell proliferation [23,24]. The role of MIF in
the brain is far less known, but MIF may critically affect
the inflammatory reaction under pathological conditions
[25-27].
MIF is rapidly and persistently up-regulated around
the infarct core after focal cerebral ischemia in rodents
[28-30]. Moreover, MIF was shown to increase in the
plasma of stroke patients within the first 3 days and
positively correlated to the severity of neurological defi-
cits [28]. We previously found that Mif
-/- (MIF-KO)
mice have a smaller infarct volume than the respective
wild-type (WT) littermates and perform significantly
better when tested for sensory-motor deficits at 48 h
and 7 days after transient MCAo (tMCAo), [29]. A simi-
lar outcome was found after spinal cord injury [31]. We
further observed that environmental enrichment 2 to 5
days subsequent to permanent MCAo in rats down-reg-
ulates MIF in the peri-infarct region and, more distally,
in the cingulate cortex, when compared to standard
housing conditions [30]. Collectively, these results indi-
cate that MIF promotes cell death and represses the
recovery of neurological function in experimental cen-
tral nervous system injury.
The up-regulation of MIF in the peri-infarct region
occurs in neurons at least up to 72 hours after tMCAo
[29]. Neuronal MIF expression per se promotes neuro-
nal death and/or renders neuronal networking more
susceptible to excitotoxic [31] and ischemia-like [29]
conditions-induced death, and it may further affect plas-
ticity events [30,32]. Whereas MIF acts as an upstream
regulator of inflammatory/immune reactions after stroke
remains to be determined.
Here, we quantified the expression of Th1/Th2 cyto-
kines in the brain and serum, and the spleen weight of
WT and MIF-KO mice during the first week after
tMCAo. Additionally, we studied the effect of the
genetic deletion of MIF in mice on reactive astrogliosis,
and number of MIF receptor (CD74)-positive inflamma-
tory cells within the injured brain hemisphere.
Material and Methods
Animal housing conditions and ethical considerations
Mice were housed in climate controlled rooms under a
12 h light-12 h dark cycle, with ad libitum access to
water and food. Animal experiments were conducted
according to protocols approved by the Malmö/Lund
Ethical Committee for Animal Research.
Strains and genotyping
We used 9 to 14 weeks old C57BL/6 male mice (pur-
chased from Taconic, Denmark) only when characteriz-
ing the expression of MIF in the brain after transient
middle cerebral artery occlusion (tMCAo).
To determine if MIF affects the inflammatory/immune
response upon tMCAo, we used Mif
+/+ (WT) and Mif
-/-
(MIF-KO) male mice, littermates, on a pure C57BL/6
background [33], 8 to 36 weeks old. These experiments
were performed in a blinded and randomized fashion.
Transient middle cerebral artery occlusion (tMCAo)
We induced focal cerebral ischemia in mice by occlud-
ing the right middle cerebral artery (MCA) for 45 min
as described in [29]. In summary, mice were initially
anesthetized by inhalation of 2.5% isoflurane (IsobaVet,
Schering-Plough Animal Health, UK) in O2:N2O (30:70).
Thereafter, mice were placed on a heating pad and
anesthesia was subsequently reduced to and maintained
at 1.5-1.8% (using an open mask). We used a rectal tem-
perature probe to monitor body temperature, kept at
approximately 37°C. An optical fiber probe (Probe 318-I,
Perimed, Sweden) was firmly attached to the skull and
connected to a laser Doppler flow meter (Periflux Sys-
tem 5000, Perimed), allowing us to monitor changes in
local/regional cerebral blood flow (rCBF). We then
inserted a filament composed of a 6-0 polydioxanone
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with a diameter of 225 to 275 μm( d e p e n d i n go nt h e
age of the animal) into the lumen of the external carotid
artery via a small wall incision. We advanced the fila-
ment up to the origin of the MCA, given by a sudden
drop in rCBF. The filament was retracted 45 min after
and reperfusion observed. Bupivacaine (0.150 μL, 0.05%,
Marcain™, AstraZeneca, Sweden) was injected around
the wound to reduce pain. In order to avoid post-surgi-
cal hypothermia, animals were placed in an incubator at
35°C for the first 2 hours after occlusion and then trans-
ferred to an incubator at 33°C (overnight). At 30 min
and 24 h post-surgery, we administered 0.5 mL of 5%
g l u c o s ei ns a l i n es u b c u t a n e ously. In animals allowed to
recover for 7 days, we further administered 0.5 mL of
5% glucose subcutaneously every 12
th hour up to day 4
post-surgery (which is when weight loss ceases). Body
weight was controlled daily up to the experimental end-
point. Additionally, we assessed temperature and gross
sensory-motor deficits at 1 h, 2 h and 24 h after occlu-
sion. In sham-surgeries, the filament was advanced up
to the internal carotid artery, and withdrawn before
reaching the MCA.
Mice that did not verify an immediate reduction in
rCBF upon MCAo and reperfusion (approximately 8%)
were immediately sacrificed and excluded from the
study; intracerebral hemorrhage was confirmed in all
the cases by analysis of 1 mm thick brain slices.
2,3,5-Triphenyltetrazolium chloride (TTC) staining
To verify a reproducible damage after a 45 min tMCAo,
WT mice (n = 8) were sacrificed at 24 h post-occlusion
and brains were sliced into 1 mm thick sections, using
a mouse brain matrix on ice. Sections were rinsed in
ice-cold 0.9% NaCl for 10 min, and thereafter immersed
in a aqueous solution composed of 0.01% TTC and
0.9% NaCl for 15 min at 37°C. Slices were fixed in 4%
formaldehyde and pictures were acquired using a
MicroPublisher 3.3 RTV CCD camera (QImaging,
Canada), under standardized conditions. We encircled
the contralateral hemisphere area, the ipsilateral hemi-
sphere area and the affected area (lack of TTC staining;
designated as infarct area for simplification) of each
slice using ImageJ software (National Institutes of
Health, USA). The infarct area (IA) was corrected for
shrinkage, IAcorrected = Contra/Ipsi x IA, and the
infarct volume was calculated by volumetric integration.
We obtained infarct volumes of approximately 53.8 ±
24.5 mm
3 (mean ± SD), (Figure 1 A).
Sample collection I (48 h)
We anesthetized WT and MIF-KO mice at 48 h after
sham-surgery or tMCAo, by inhalation of 2.5% isoflur-
ane. Blood (200-400 μL) was collected by heart puncture
having a minimal flow resistance to avoid hemolysis.
Thereafter, mice were perfused transcardially with 0.9%
NaCl for 2 min and decapitated. Upon removal of the
meninges, brains were quickly obtained and frozen by
immersion in isopentane at -40°C, further cooled down
to -70°C and stored at -80°C. Spleens were collected and
weighed. Blood was allowed to coagulate for approxi-
mately 30 min. After standard centrifugation, blood
serum was obtained and stored at -80°C. We dissected
both the infarct core (IC) and the remaining tissue of
the ipsilateral hemisphere, designated as non-infarct
region (NIR) for simplification, from coronal brain sec-
tions, at -15°C. At this temperature and in view of a cri-
tical difference in tissue organization, IC and NIR can
be easily detached. Specifically, we obtained consecutive
2 mm, 1 mm and 2 mm thick brain sections, starting at
2m mf r o mt h eo l f a c t o r yb u l b .I ns h a m - o p e r a t e dm i c e ,
we dissected equivalent brain regions, also designated as
IC and NIR. A schematic representation of the dissec-
tions is included in the Results section.
Brain cytokines Brain IHC
tMCAo
Sham
48 h Day 7
Blood serum cytokines
Spleen weight
Blood serum cytokines
Spleen weight
Figure 1 Experimental settings. (A) Composite photograph of a TTC stained brain 24 h after tMCAo. Representation of the cerebral damage
obtained in average after a 45 min occlusion of the right middle cerebral artery, in C57BL/6 mice (white). Scale bar: 3 mm. (B) Experimental
outline. IHC, immunohistochemistry.
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At day 7 after tMCAo, C57BL/6 mice (Taconic), WT
a n dM I F - K Om i c ew e r ea n e s t h e t i z e da n dp e r f u s e d
transcardially with 0.9% NaCl for 2 min followed by 4%
formaldehyde. For the WT and MIF-KO mice, we col-
lected blood prior to saline/fixative perfusion; spleens
were obtained and weighed. All the brains were kept in
fixative overnight, transferred to 30% sucrose (in PBS),
and subsequently cut into 30 μm-thick coronal sections
(free-floating).
The experimental outline is presented in Figure 1 B.
Protein Extraction and cytokines/chemokines
immunoassay
Whole cellular protein extractions from the dissected IC
and NIR were performed by mechanical homogenization
and incubation in lysis buffer: 20 mM Tris (pH 7.5), 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-
X100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerol-
phosphate, 1 mM orthovanadate, 1 mM PMSF, supple-
mented with a protease inhibitor cocktail (P8340,
Sigma-Aldrich, Germany). Following 30 min incubation,
samples were centrifuged at 18000 xg, for 15 min. Total
protein concentration was determined by the Bradford
assay, using bovine albumin (Sigma-Aldrich) as stan-
dard. Interferon (IFN)-g, interleukin (IL)-10, IL-12, IL-
1b, IL-2, IL-4, IL-5, tumor necrosis factor (TNF)-a and
keratinocyte-derived cytokine (KC)/CXCL1 protein
levels were determined byas a n d w i c hi m m u n o a s s a y
essentially according to the manufacturer’s recommen-
dations (ultra-sensitive protocol, Meso Scale Discovery,
USA) and using a SECTOR Imager 6000 (Meso Scale
Discovery). A few modifications were introduced: for
assays including brain samples, standards were dissolved
in lysis buffer; brain extracts and serum were incubated
with the capture antibody for 4 h. The results corre-
spond to the protein concentration (pg/mL) when using
150 μg of protein per brain sample (in 50 μL per well);
serum was assayed undiluted (30 μL per well).
General immunohistochemistry
Formaldehyde-fixed free-floating brain slices were rinsed
three times in phosphate-buffered saline (PBS) and
thereafter kept in a 5% blocking solution (5% normal
serum, Jackson ImmunoResearch, UK, and 0.25% Triton
X-100 in PBS) for 1 h at room temperature. Sections
were then incubated with primary antibody/antibodies
diluted in 2% blocking solution overnight at 4°C
(Table 1). Next, sections were rinsed three times (in
PBS) and incubated with secondary antibody/antibodies
conjugated with the fluorescent dyes Cy3, Cy5 (Jackson
ImmunoResearch) and Alexa488 (Molecular Probes,
Invitrogen, UK), except when using a GFAP-Cy3 direct
conjugate. When detecting the primary antibody by the
biotin-avidin-horseradish peroxidase system (VECTAS-
TAIN Elite ABC kit, Vector Laboratories, UK), brain
sections were quenched in 3% H2O2/10% methanol for
15 min and rinsed prior to blocking. We used all the
secondary antibodies at a dilution of 1:400. Fluorescence
was detected by laser-scanning microscopy (LSM 510,
Zeiss, Germany), except when indicated, using equal set-
tings among experimental conditions. We acquired
bright-field micrographs with an Olympus BX60 micro-
scope (Olympus, Sweden), except when indicated, using
standard conditions among sections.
GFAP and CD74 immunohistochemistry
We detected GFAP and CD74 in brain sections of WT
and MIF-KO mice sacrificed 7 days after tMCAo by
immunohistochemistry. We used a monoclonal anti-
GFAP antibody (1:2500, Sigma-Aldrich) and suitable
Cy3-conjugated secondary antibody; the anti-CD74 anti-
body (1:200, BD Pharmingen, Sweden) was visualized by
the biotin-avidin-horseradish peroxidase system. We
used three brain sections per animal, corresponding
approximately to the following levels: 1.18, 0.50 and
-1.82 mm, in relation to bregma. Accordingly, fluores-
cence and bright field micrographs of the ipsilateral
brain hemisphere represented in each section were
acquired (in grayscale) under a 10X objective, using a
Nikon Eclipse 80i microscope and the NIS-Elements
software (Nikon, Solna, Sweden). Pictures were acquired
using the same settings, respectively. Final composite
images were subsequently generated by NIS-Elements
software.
Analysis of the cerebral GFAP immunoreactivity
When analyzing cerebral GFAP immunoreactivity
(GFAP-ir), we considered the following parameters: 1)
GFAP
+ area within each composite image, excluding the
Table 1 Primary antibodies
Primary antibody Supplier Catalogue Dilution
Rabbit anti-MIF Torrey Pines Biolabs TP234 1:300-
1:5000
Mouse anti-Tuj1 Chemicon (Millipore) MAB1637 1:500-
1:800
Mouse anti-
Parvalbumin
Sigma-Aldrich P3088 1:4000-
1:6000
Mouse anti-GST-p BD Transduction
Laboratories
610718 1:500
Rat anti-Mac2,
biotinylated
Acris Antibodies CL049B 1:500
Mouse anti-GFAP,
Cy3
Sigma-Aldrich C9205 1:5000
Mouse anti-GFAP Sigma-Aldrich 3893 1:2500
Rat anti-CD31 BD Pharmingen 550274 1:200
Rat anti-CD74 BD Pharmingen 555317 1:200
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the encircled area, 3) signal intensity within the ipsilat-
eral hippocampus, and 4) cortical and subcortical widths
of the GFAP-ir. In particular, we measured four cortical
widths. For that purpose, we considered four virtual
lines (from the top to the bottom of the cortex), divid-
ing the cortex in approximately three equal parts; these
lines intercepted the cortical infarct core/peri-infarct
core border zone (virtual line) in an angle similar to
that of the natural orientation of the cortical layers. We
determined the subcortical width at the ventral-dorsal
level 2.8 mm (close to the ventricle wall) and 1.0
(nucleus accumbens). Two persons blinded to the ani-
mal groups evaluated all the parameters independently.
CD74 counts
We estimated the number of CD74
+ cells within each
section by 1) encircling the CD74
+ area within each com-
posite image (roughly, the infarct core), 2) setting a signal
intensity threshold for each composite image, and 3) an
automated counting of CD74
+ particles, using NIS-Ele-
ments software. We present the results as the total num-
ber of particles detected per brain. The light conditions
at acquisition across images (background) were evaluated
prior to setting the threshold; four slightly different
thresholds were used according to the specific image
background. Importantly, the background did not differ
significantly between WT and MIF-KO mice neither did
the selected threshold level. Given that MIF-KO mice
have smaller infarct volumes than WT littermates [29],
we further analyzed the particles area and the fraction
particles area/encircled area p e rs e c t i o n .W ea l s oa n a -
lyzed CD74-ir in terms of signal intensity within the
encircled area, signal intensity of the selection upon set-
ting the threshold, and mean intensity per particle.
Statistics
Data are presented as means ± standard deviation (SD),
unless otherwise specified. For all the statistical tests,
results were considered significant when p < 0.05. The
concentration of each of the inflammatory mediators
included in this study, as well as the IC, NIR and serum
were analyzed independently. Differences among groups
(WT and MIF-KO mice, subjected to either sham-sur-
gery or tMCAo), were assessed by 2-way analysis of var-
iance and post-hoc by the Tamhane’s test. With respect
to the GFAP and CD74 evaluations, each of the para-
meters included in the experimental design was tested
separately. To compare respective differences between
the two experimental groups (WT and MIF-KO mice
subjected to tMCAo) we used the Student’s t-test. For
each parameter, we further evaluated putative brain
level-specific differences (between WT and MIF-KO
mice) by the Student’s t-test.
Results
Cerebral MIF expression in C57BL/6 mice 7 days after
tMCAo
We previously characterized the spatial-temporal expres-
sion of MIF (protein) in the brains of C57BL/6 mice up
to 72 h after 45 min tMCAo. In the present study, we
further investigated the expression of MIF (protein) in
the brains of C57BL/6 mice 7 days after 45 min tMCAo,
by immunohistochemistry (n = 2-13).
Within the first 72 h post-occlusion, MIF immunor-
eactivity (MIF-ir) increased in the peri-infarct region,
particularly in the peri-infarct cortex. Somewhat surpris-
ingly, this increase occurred primarily in neurons,
including parvalbumin-containing interneurons [29].
Between 72 h and 7 days after tMCAo, the cellular dis-
tribution of MIF in the peri-infarct region changed
markedly. Figure 2 A exemplifies the observed expres-
sion of MIF in the motor/somatosensory cortex at day 7
post-occlusion. At this time-point, MIF-ir remained
relatively elevated in Tuj-1
+ cells (neurons) of the peri-
infarct cortex, and the accumulation in parvalbumin-
containing cells (presumably interneurons) was still evi-
dent (Figure 2 B). Additionally, MIF was found in GFAP
+ cells closely surrounding the infarct core, putative
reactive astrocytes (Figure 2 B). In line with previous
time-points, we did not observe MIF-ir in GST-π
+ oligo-
dendrocytes at day 7 of recovery (Figure 2 C).
Up to 72 h after stroke, the baseline cellular MIF-ir is
lost within the infarct core, where merely a diffuse
immunoreactivity pattern could be observed [29].
Between 72 h and 7 days after tMCAo, major changes
in the expression of MIF occurred also in the infarct
core (Figure 3 A). At day 7, and while still reduced in
comparison to that in the peri-infarct region, MIF
expression in the infarct core appeared in glial-like cells
that surround CD31
+ endothelial cells, and in galectin-3
+ (Mac-2
+) microglia/macrophages (Figure 3 B).
Antibody specificity for MIF was confirmed by the
lack of immunoreactivity in the brains of MIF-KO mice,
as shown before [29].
Expression of inflammatory mediators in the brain and
serum of WT and MIF-KO mice 48 h and 7 days after
tMCAo
We determined the expression of eight inflammatory
mediators at the protein level in the brain and serum of
WT and MIF-KO mice subjected to 45 min tMCAo and
allowed to recover for either 48 h or 7 days. Mice sacri-
ficed 48 h after sham-operation were included. Specifi-
cally, brains were collected 48 h and sera (and spleens)
collected at both 48 h and 7 days after surgery. Table 2
summarizes the number of mice tested per experimental
condition. Importantly, rCBF at MCA occlusion and
reperfusion, body temperature, body weight and
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the cerebral infarct core (IC) and non-infarct region
(NIR) as represented in Figure 4 A.
Of the eight inflammatory mediators quantified (in
brain and serum samples), only cerebral IL-12 and KC
(also known as CXCL-1/CINC-1) protein concentrations
differed significantly among the groups (Figure 4 B and
4C, respectively). We obtained a higher IL-12 protein
concentration in the infarct core of WT mice subjected
to tMCAo (74.6 ± 38.4 pg/mL, n = 11), than in the cor-
responding region of WT mice subjected to sham-
operation (8.9 ± 1.8 pg/mL, n = 6), p = 0.001. A stroke-
induced increase in IL-12 protein concentration
occurred also in the non-infarct region of WT mice: 8.2
± 1.8 pg/mL (sham, n = 6) and 48.4 ± 24.1 pg/mL
Figure 2 MIF accumulates in neurons and astrocytes of the
peri-infarct region during the first 7 days after tMCAo, in
C57BL/6 mice. (A) Bright field micrographs. Representative image
of MIF immunoreactivity (MIF-ir) in the peri-infarct motor/
somatosensory cortex at 7 days after tMCAo. Scale bar: 100 μm
(right). A higher magnification image denotes the expression in
neurons and glia-like cells. Note the thick glia-like processes positive
for MIF around the infarct core. Scale bar: 50 μm (left). (B) Confocal
micrographs. Co-localization of MIF (Cy3, red) with the neuronal
markers Tuj-1 and PV (both Cy5, green). Co-localization of MIF (Cy3,
red) and the marker GFAP (Cy5, green) confirms the presence in
reactive astrocytes. Scale bar: 50 μm. Infarct core-IC. (C) Confocal
micrographs. Lack of co-localization of MIF (Cy3, red) and GST-π
(Cy5, green) in the peri-infarct somatosensory-motor cortex at 7
days after occlusion. Scale bars: 50 μm and 20 μm (lower and
higher magnification, respectively).
Figure 3 Expression of MIF in the infarct core of C57BL/6 mice
at day 7 after tMCAo. (A) Representative bright field image of the
striatal infarct core. Scale bar: 50 μm. (B) MIF is expressed in glia-like
cells surrounding CD31
+ cells, upper panel. Scale bar: 50 μm. Co-
localization of MIF (Cy3, red) with the microglial/macrophage
protein galectin-3(Gal-3)/Mac-2 (Alexa488, green), lower panel. Scale
bar: 50 μm.
Table 2 Number of WT and MIF-KO mice used per
experimental condition
48 h 7 days
Sham tMCAo tMCAo
WT 4-6 8-11 10
MIF-KO 4-6 8-12 9
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Figure 4 Genetic deletion of MIF does not affect the cerebral up-regulation of IL-12 and mKC 48 h after tMCAo, in mice. A) Schematic
representation of the regions dissected from brains collected 48 h after surgery (sham and tMCAo): infarct core (IC, white) and non-infarct
region (within dotted line). Scale bar: 3mm. B and D) IL-12 and mKC protein levels in the cerebral IC and non-infarct region (NIR) of WT and
MIF-KO subjected to sham-operation or tMCAo. D and E) IL-12 and mKC protein levels in the serum of WT and MIF-KO 48 h and 7 days after
sham-operation or tMCAo. In B, C, D and E we present individual data points and the mean (dash). # p < 0.05 tMCAo IC versus Sham IC (for
each genotype). § p < 0.05 tMCAo NIR versus Sham NIR (for each genotype).
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regulated in the brain of MIF-KO mice following
tMCAo versus sham-surgery: infarct core, 10.2 ± 2.2 pg/
mL (sham, n = 6) and 61.5 ± 22.0 pg/mL (tMCAo, n =
12), p<0.0001; non-infarct region, 11.0 ± 4.5 pg/mL
(sham, n = 6) and 83.5 ± 64.4 pg/mL (tMCAo, n = 12),
p<0.05. However, we did not obtain significant differ-
ences between the two genotypes.
We found a robust up-regulation of KC in the infarct
core of WT mice subsequent to tMCAo (212.1 ± 187.2
pg/mL), in comparison to sham-surgery (4.7 ± 3.3 pg/
mL), p < 0.05. To a lower extent, KC also was induced
in the non-infarct region of WT mice following stroke:
4 . 9±3 . 3p g / m L( s h a m )a n d2 7 . 6±1 6 . 6p g / m L
(tMCAo), p < 0.01. We detected similar values in brain
samples from MIF-KO mice: infarct core, 4.0 ± 1.7 pg/
mL (sham) and 167.1 ± 94.2 pg/mL (tMCAo), p < 0.001;
non-infarct region, 4.5 ± 2.2 pg/mL (sham) and 22.0 ±
8.5 pg/mL (tMCAo), p < 0.0001. Hence, we did not find
differences between genotypes.
The cerebral up-regulations of IL-12 and KC were not
accompanied by significant changes in the respective
serum concentrations 48 h and 7 days after stroke, and
similar values were obtained in WT and MIF-KO mice
per condition (Figure 4 D and 4E, accordingly).
With respect to the protein levels of IFN-g,I L - 2 ,I L -
4, IL-5, IL-10 and TNF-a in the brain, we did not find
significant differences induced by stroke or by the
d e l e t i o no fM I F( F i g u r e5A ,B ,C ,D ,Ea n d5 F ,r e s p e c -
tively). Nevertheless, we obtained a strong trend
towards a stroke-induced increase in the levels of IL-
10 in the infarct core (p = 0.06). A strong trend
towards an effect of stroke depending on the genotype
on the levels of IL-10 in the non-infarct region also
was obtained (p = 0.05). No differences in cytokines/
chemokines levels were found in the serum (Figure 6
A, B, C, D, E and 6F).
Spleen weight of WT and MIF-KO mice 48 h and 7 days
after tMCAo
We further studied a putative effect of MIF on the
spleen weight of mice during the first week post-stroke.
The spleen weights of sham-operated WT (n = 6) and
MIF-KO (n = 6) mice were not significantly different
(Figure 7 A): 0.089 ± 0.021 g and 0.133 ± 0.029 g,
respectively. At 48 h after tMCAo, the spleen weight did
not differ significantly between WT (0.090 ± 0.031 g, n
= 11) and MIF-KO (0.100 ± 0.043 g, n = 12) mice (Fig-
ure 7 A). At this time point post-occlusion, the spleen
weight was similar to the baseline (i.e., sham-operated
animals), for both genotypes. Moreover, the deletion of
Mif in mice did not affect spleen weight up to 7 days
after tMCAo (Figure 7 A1): 0.059 ± 0.013 g, WT mice
(n = 13); 0.071 ± 0.024 g, MIF-KO mice (n = 9).
As previously indicated we did not detect significant
differences in body weight before and body weight/
weight loss after surgery between genotypes. Yet, we
normalized spleen weight to body weight. Also in this
case, we did not obtain a significant difference between
genotypes (Figure 7 B and 7B1).
GFAP immunoreactivity in the cerebral peri-infarct region
of WT and MIF-KO mice 7 days after tMCAo
The up-regulation of intermediate filament proteins,
such as GFAP, is a hallmark of reactive astrogliosis,
including glial scar formation bordering the infarct core
after stroke [10]. To determine if MIF affects the extent
of reactive astrogliosis, we studied GFAP immunoreac-
tivity (GFAP-ir) in the brains of WT and MIF-KO mice,
7 days post-occlusion. Figure 8 exemplifies the obtained
cerebral GFAP-ir within the ispilateral hemisphere. We
did not detect a critical difference between the WT (n =
12-13) and MIF-KO (n = 9) groups with respect to all
of the quantified parameters, i.e., area of GFAP-ir
(excluding the hippocampus), signal intensity within the
GFAP
+ area, signal intensity within the ipsilateral hippo-
campus, and width of GFAP-ir. We did not detect over-
all or brain level-specific differences between genotypes
(data not shown).
Number of CD74
+ cells in the cerebral infarct core 7 days
after tMCAo in WT and MIF-KO mice
Previous studies suggest that MIF modulates the infiltra-
tion of inflammatory/immune cells into the brain par-
enchyma under pathological conditions. It is known that
MIF acts on the cell surface receptor CD74 [34],
expressed in antigen-presenting cells, or APC’s [35]. We
found that CD74
+ cells, putative APCs, accumulate in
the brains of C57BL/6 mice during the first week after
stroke [36]. We thus hypothesized an effect of the
genetic deletion of MIF in mice on the number of CD74
+ cells within the brain 7 days post-tMCAo.
We first examined in more detail the expression of
CD74 in the mouse brain (WT) 7 days after tMCAo
(using immunohistochemistry). CD74
+ cells appeared
essentially in the injured brain hemisphere, clearly
within the infarct core, determined by the lack of NeuN
immunoreactivity (Figure 9). While varying among indi-
viduals (n = 15), the distribution of CD74
+ cells often
comprised a clear higher density rim within the cortex
(as exemplified in Figure 9 A); in some cases, a com-
plete high-density rim shaping the infarct core, but
within its boundaries could be found. Moreover, CD74
+
cells exhibited diverse morphologies (Figure 9 A1). Up
to 7 days after tMCAo, we could not find CD74 expres-
sion in brain cells. We found CD74
+ cells in the cerebral
infarct core as early as 3 days, but not to the same
extent as at 7 days post-tMCAo (data not shown).
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+ cells were at 7 days in close vicinity
with MIF
+ cells, we did not find CD74/MIF double-
labeled cells (Figure 9 B).
Finally, we found a similar number of CD74
+ parti-
cles per brain (that we refer to as CD74
+ cells, for sim-
plification) in WT (n = 12) and MIF-KO mice (n = 9):
10111 ± 4058 and 8947 ± 2346, respectively (p = 0.45),
(Figure 9 C). Additionally, the area of CD74-ir (or
encircled area) per section was similar between the
groups. Importantly, we found no difference in the
particles area per section, neither in the fraction parti-
cles area/encircled area per section between groups.
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Page 9 of 15The CD74-ir (signal intensity) did not differ between
genotypes.
Discussion
We will discuss the primary findings of the study: the
expression of MIF in the mouse brain is highly dynamic
(1); the deletion of Mif in mice does not affect the
expression of Th1/Th2 cytokines in the brain and serum
(2), spleen weight (3), reactive astrogliosis (4) and num-
ber of CD74
+ cells in the brain (5); after stroke.
MIF and the expression of Th1/Th2 cytokines in the
mouse brain and serum after stroke
We previously found that disruption of Mif in mice (on
a C57BL/6 background) results in a smaller cerebral
infarct volume and in a lower extent of sensory-motor
75
125
Serum IL-2 B
130
230
Serum IFN-J A
25
75
10
5
0
15
Sham tMCAo tMCAo
p
g
/
m
L 30
130
10
5
0
15
Sham tMCAo tMCAo
p
g
Serum IL-5 D
Sham tMCAo
48 h
tMCAo
7 d
Serum IL-4
Sham tMCAo
48 h
tMCAo
7 d
885 125
p
g
Sham tMCAo tMCAo
85
485
20
10
0
30
40
p
g
/
m
L
Sham tMCAo tMCAo
25
75
10
5
0
15
Serum IL-10 Serum TNF-Į F
Sham tMCAo
48 h
tMCAo
7 d
Sham tMCAo
48 h
tMCAo
7 d
9000
3.0
100
1000
5000
200
0
300
Sham tMCAo tMCAo
p
g
0.0
Sham tMCAo tMCAo
p
g
/
m
L
2.0
2.5
1.0
0.5
1.5
WT MIF-KO
Sham tMCAo
48 h
tMCAo
7 d
Sham tMCAo
48 h
tMCAo
7 d
Figure 6 Serum IFN-b,I L - 2 ,I L - 4 ,I L - 5 ,I L - 1 0a n dT N F - a protein levels 48 h and 7 days after tMCAo, in WT and MIF-KO mice.P r o t e i n
concentration in pg/mL; we show individual data points (as indicated in the figure) and the mean (dash). IC, infarct core; P, peri-infarct region.
Inácio et al. Journal of Neuroinflammation 2011, 8:75
http://www.jneuroinflammation.com/content/8/1/75
Page 10 of 15deficits during the first week after stroke. In particular,
MIF-KO mice performed significantly better than WT lit-
termates at both the rotating pole and grip strength tests
48 h after tMCAo. At this time point, i.e., 48 h after
tMCAo, the expression of IL-1b increased in the cerebral
infarct core (but not in the serum). Importantly, we
obtained similar IL-1b protein levels in the brain and
serum of WT and MIF-KO mice [29]. Here, we analyzed
the expression of eight additional Th1/Th2 cytokines, also
at the protein level. While stroke resulted in a significant
increase in IL-12 and mKC protein levels in the brain [37]
(infarct core and non-infarct region), we did not detect an
effect of the genotype on the expression of the inflamma-
tory mediators analyzed, in the brain and serum.
It has become a general concept that MIF promotes
the production/release of pro-inflammatory cytokines
upon inflammatory stimulus [19]. For instance, MIF-KO
mice (C57BL/6 x Sv129, males) have lower circulating
IFN-g, IL-12 and TNF-a protein levels (diminished Th1
response) upon Salmonella typhimurium infection [38].
Of particular relevance, the expression of several cyto-
kines in the brain, including IFN-g, IL-12 and TNF-a,a t
mRNA level is lower is MIF-KO mice (BALB/C females)
upon West Nile Virus infection [26]. This was accompa-
nied by a decrease in TNF-a (protein) in the serum and
by a decrease in splenic IL-12 (mRNA). The authors dis-
cuss that a decrease in cytokine expression in the brain
may however result from a decreased viral neuroinva-
sion. Recently and apart from infection, Gao et al.
showed a decrease in classical pro-inflammatory cyto-
kines, including IL-1b and TNF-a, as well as an increase
in IL-10 protein levels in the myocardium of MIF-KO
versus WT mice (on a C57BL/6 background, male) fol-
lowing 60 min ischemia and 24 h reperfusion [39].
Here, it is also possible that the altered cytokine produc-
tion depends primarily on a smaller infarct obtained for
MIF-KO mice.
In fact, the exact pattern of modifications in cytokine
production in the presence or absence of MIF varies
across studies. For instance, IL-1b can be down-regu-
lated [39], up-regulated [38] or unchanged [26] in MIF-
KO mice upon inflammatory stimulus. Moreover, in a
mouse model of multiple sclerosis, experimental autoim-
mune encephalomyelitis, no significant differences in the
peripheral levels of IL-10, IL-17, or IFN-g between MIF-
KO mice (on a C57BL/6 background, males) and WT
controls were observed [27]. In line with our results, the
authors suggest that MIF is not required for Th1-
mediated immunity, and that the deletion of MIF does
not result in a shift to a Th2 response.
A
0.120
0.160
4
8
 
h
 
(
g
)
0.120
0.160
A1
7
 
d
 
(
g
)
0.000
0.040
0.080
Sham tMCAo
S
p
l
e
e
n
 
w
e
i
g
h
t
 
4
0.000
0.040
0.080
WT KO
S
p
l
e
e
n
 
w
e
i
g
h
t
 
B B1
00 0 0
0.001
0.002
0.003
0.004
0.005
S
p
l
e
e
n
 
w
/
b
o
d
y
 
w
 
4
8
 
h
0 000
0.001
0.002
0.003
0.004
0.005
S
p
l
e
e
n
 
w
/
b
o
d
y
 
w
 
7
 
d
B B1
WT
MIF-KO
0.000
Sham tMCAo
S
0.000
WT KO
Figure 7 Spleen weight of WT and MIF-KO mice up to 7 days after tMCAo. Spleen weight (in g; mean ± STD) of WT and MIF-KO mice 48 h
after either sham-surgery or tMCAo (A) and 7 days after tMCAo (A 1), and respective spleen weight (g)/body weight (g) ratios (B and B 1).
Inácio et al. Journal of Neuroinflammation 2011, 8:75
http://www.jneuroinflammation.com/content/8/1/75
Page 11 of 15Despite differences in experimental models, it is
becoming increasingly evident that the effect of MIF
depends on the type of cellular stimulus, spatial-tem-
poral context of MIF expression, and respective concen-
tration range [40], and eventually on the disease stage
[38]. Our data suggests that while promoting neuronal
death and aggravating neurological deficits, MIF expres-
sion is not essential in driving the production of Th1/
Th2 cytokines post-stroke, at least at the time-points
studied.
Spleen weight after tMCAo in mice
We did not detect a difference in spleen weight between
WT and MIF-KO mice under control conditions (sham-
operations) or after tMCAo, and we are not aware of
previously reported differences in spleen weight or his-
tological parameters caused by the deletion of MIF [38].
The apparent reduction in spleen weight at day 7 post-
stroke versus sham is in convergence with previous stu-
dies [18]. However, stroke-induced splenic atrophy was
no longer apparent after the normalization spleen
weight/body weight, indicating that weight loss corre-
lates with and may even precede spleen atrophy after
experimental stroke.
MIF and reactive gliosis
We observed that MIF is expressed in GFAP
+ cells sur-
rounding the infarct core (or reactive astrocytes) 7 days
after tMCAo in C57BL/6 mice. This is line with our
previous observation that MIF is highly expressed in
reactive astrocytes (of the peri-infarct region) at 5 days
after permanent MCAo in rats [30]. These results indi-
cate that the up-regulation of MIF is part of a conjunct
of molecular alterations that is on the basis of reactive
astrogliosis and eventually glial scar formation after
stroke [10]. Moreover, factors known to induce MIF
expression, such as hypoxia-related factors [28,41] and
cytokines [42], also are known to induce reactive astro-
gliosis, and these two processes may be highly inter-
connected.
We reported previously that housing rats in an
enriched environment 2 to 5 days subsequent to perma-
nent MCAo, a paradigm that dramatically improves sen-
sory-motor function without altering infarct volume,
results in a down-regulation of MIF protein levels
around the infarct core (at 5 days post-stroke) [30].
Importantly, the down-regulation of MIF was not sec-
ondary to a decrease in reactive astrogliosis/glial scar
formation, given by an unchanged GFAP protein level
between housing conditions. These results implicate that
a lower astrocytic MIF content correlates with an
improved sensory-motor function in rats, 5 days after
stroke. Here, we found a similar GFAP-ir in the brains
(damaged hemisphere) of WT and MIF-KO mice at 7
days post-tMCAo further suggesting that MIF is not
essential for but is part of reactive astrogliosis. Overall, a
reduced expression or abrogation of MIF in astrocytes
may underlie an improved functional recovery, particu-
larly long-term, after stroke. Although previously under-
stated, molecular alterations in reactive astrocytes are
believed to affect among others neuronal function,
microglial function and immune cell invasion, and
thereby the outcome following stroke [43].
We previously observed that MIF-KO mice show a
similar CD68 immunoreactivity, but a higher Gal-3
immunoreactivity within the injured brain hemisphere 7
days following experimental stroke, in comparison to
WT littermates [29]. These results suggest that MIF
modulates the microglia/macrophages response follow-
ing stroke. This may occur via an increase in the expres-
sion of Gal-3, an increase in the proliferation of Gal-3
+
cells and an increase in the infiltration of monocytes
into the brain parenchyma [26,27]. Macrophages are a
known source of MIF [42]. Here, we found that MIF is
Figure 8 Cerebral GFAP immunoreactivity at day 7 post-
tMCAo, in mice. Composite image representing the obtained GFAP
immunoreactivity (Cy3, gray-scale) within the right brain hemisphere
7 days after a 45 min occlusion of the right middle cerebral artery,
in C57BL/6 mice (epifluorescence micrographs).
Inácio et al. Journal of Neuroinflammation 2011, 8:75
http://www.jneuroinflammation.com/content/8/1/75
Page 12 of 15expressed in Gal-3
+ cells, microglia/macrophages, within
the infarct core 7 days after tMCAo.
The particular expression of MIF in glial cells may
underlie the modifications in the microglia/macrophages
response here in cause. However, the exact mechanism
(s) of action of MIF in astrocytes and in microglia, or at
the interface among neurons, astrocytes, microglia and
immune cells remain(s) to be identified.
MIF and immune cell recruitment
MIF may promote [26,27] or inhibit [25] immune cell infil-
tration into the brain parenchyma under pathological con-
ditions. In particular, Bacher et al. (2002) proposed that
the induction of MIF in end-feet astrocytes at the blood-
brain barrier (BBB) inhibits macrophage infiltration into
the brain upon Borna Disease Virus infection [25]. Besides
the accumulation in astrocytes and microglia, we observed
Figure 9 Number of CD74
+ cells in WT and MIF-KO brains 7 days after tMCAo. (A and A1) Epifluorescence micrographs. (A) Representative
composite image of CD74 immunoreactivity in the mouse brain 7 days post-occlusion (WT). Note the presence of CD74
+ cells essentially within
the infarct core. (A1) Higher magnification micrographs denote the morphology of CD74
+ cells. Scale bar: 10 μm. (B) Confocal images. Lack of
co-localization MIF (Alexa 488, green)/CD74 (Cy3, red) in the infarct core. Scale bars: 50 μm and 10 μm (lower and higher magnification,
respectively). (C) Number of CD74
+ cells detected per ipsilateral brain hemisphere (sum of the analyzed brain levels) - WT and MIF-KO mice 7
days post-occlusion of the MCA (mean ± STD).
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sels within the infarct core 7 days after tMCAo. The parti-
cular accumulation of MIF in glial-like cells surrounding
blood vessels may influence immune cell infiltration into
the brain parenchyma [44]. Here, we further evaluated the
effect of genetic deletion of MIF in mice on the number of
CD74
+ cells within brain. First, CD74, also known as major
histocompatibility complex (MHC) class II-associated
invariant chain (li), is a cell surface MIF-receptor [34]. Sec-
ond, CD74 may play a role in CNS injury [45]. Third, we
previously found a lower number of CD74
+ cells in the
brains of legumain-deficient mice, when compared to the
brains of WT littermates, suggesting that either the expres-
sion of this protein or more likely the recruitment of these
cells is regulated by the expression of inflammatory/
immune cues after stroke [36]. CD74 is not expressed in
brain cells, and the absence of MIF did not affect the num-
ber of CD74
+ cells within the injured brain hemisphere,
suggesting that the MIF-CD74 signaling is not involved in
brain function after stroke.
The overall lack of an effect of the genetic deletion of
MIF in mice suggests that alternative inflammation-
related and/or unrelated mechanisms may be involved.
Based on previous in vivo and in vitro experiments
[29,31,32], it is tempting to speculate that the upregula-
tion of MIF in neurons underlies the observed deleter-
ious effects, at least during the first week post-stroke in
mice. Beyond an eventual neuroimmunomodulatory
role, it is possible that MIF acts primarily as neuromo-
dulator in the brain.
Conclusion
Our data indicates that MIF does not affect main compo-
nents of the inflammatory/immune response following
stroke. The expression and regulation of MIF in neurons
may be primordial in the development of the infarct and
neurological deficits, whereas the (over)expression in
astrocytes and microglia, and the modulation of microglia/
macrophages response may further depress the recovery
of lost neurological function. The broad spectrum of MIF
actions and the complexity of MIF expression in the brain
post-stroke challenge the identification of the exact mode
or modes of action of MIF in cerebral ischemia.
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